Confirmed title: Diazomethane: embracing hazardous chemistry at scale and through the utilisation of flow chemistry

20 June: 10:45 - 11:00

Dr Dan Stark, Development Chemist, Sterling Pharma Solutions Limited

ABSTRACT

Dr Dan Stark will be presenting Sterling Pharma Solutions capabilities for the scale-up and manufacture of complex and hazardous synthesis. Showcased through Sterling’s current work on diazomethane and the utilisation of modern flow chemistry technologies in API manufacture.

BIOGRAPHY

Dr Dan Stark completed a PhD in organic chemistry and synthetic methodology, under the supervision of Professor Andrew Smith, at the University of St Andrews. Dan then moved into industry with roles at Almac and Syngenta, working on projects ranging from lead generation discovery to kilo-scale manufacture. In 2017, Dan took up his current position at Sterling Pharma Solutions’ UK-based headquarters as a development chemist working in process R&D.

COMPANY PROFILE

Sterling Pharma Solutions is a leading API CDMO. From US FDA, MHRA and PMDA approved facilities in the UK and the US; Sterling can handle the most hazardous chemistry at a range of scales. We are passionate about providing a customer focused and service driven approach to offer flexible and tailored solutions to our clients.